{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:24Z","timestamp":1792791924180,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) is a lethal and rapidly progressive hematologic malignancy with high rates of relapse and treatment refractoriness. Management of AML is complicated by biological heterogeneity in a disease that is broadly defined by the clonal expansion of myeloblasts that otherwise play an important role in healthy marrow tissues. While subtypes of AML are increasingly defined by druggable driver mutations including\n                    <jats:italic>FLT3-ITD<\/jats:italic>\n                    ,\n                    <jats:italic>IDH1<\/jats:italic>\n                    ,\n                    <jats:italic>IDH2<\/jats:italic>\n                    , and\n                    <jats:italic>NPM1<\/jats:italic>\n                    , conventional chemotherapy and reduced intensity induction regimens (e.g., azacitidine-venetoclax) remain therapeutic backbones. One area of active development for personalization of AML treatment is the assessment of measurable residual disease (MRD). MRD testing in AML is complicated by uncertainty regarding the physiologic compartment of persistent and relapsing myeloblasts, and by increasing recognition of myeloid driver mutations in some healthy bone marrow states, such as clonal hematopoiesis of indeterminate potential (CHIP). Even in large academic centers, MRD tools are not yet universally available. Standardized workflows for MRD implementation are only beginning to enter consensus and guideline documents. Current understanding of AML biology and state-of-the-art tools for MRD measurement are reviewed here in an effort to promote clinical and laboratory investigator collaboration for the development of reliable tools for improving outcomes in this deadly disease. Clinical trial number: not applicable\n                  <\/jats:p>","DOI":"10.1007\/s10555-026-10322-5","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:27:39Z","timestamp":1774603659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-528X","authenticated-orcid":false,"given":"Joseph","family":"Van Galen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-7460","authenticated-orcid":false,"given":"Stephen D.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-8819","authenticated-orcid":false,"given":"Ashish","family":"Bains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-0250","authenticated-orcid":false,"given":"Sara H.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"10322_CR1","doi-asserted-by":"crossref","unstructured":"C, M. J., et al. (2018). Immune escape of relapsed AML cells after allogeneic transplantation. New England Journal of Medicine, 379(24), 2330\u20132341.","DOI":"10.1056\/NEJMoa1808777"},{"key":"10322_CR2","doi-asserted-by":"crossref","unstructured":"L, B., et al. (2023). Optical genome mapping in acute myeloid leukemia: A multicenter evaluation. Blood Adv, 7(7), 1297\u20131307.","DOI":"10.1182\/bloodadvances.2022007583"},{"key":"10322_CR3","unstructured":"S, B., et al. (2024). Acute lymphoblastic leukemia, Version 2.2024, NCCN Clinical Practice.\u00a0J Natl Compr Canc Netw,\u00a022(8), 563\u2013576."},{"issue":"1","key":"10322_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","volume":"6","author":"L O","year":"2025","unstructured":"O, L., Id, O., Sm, D., & Id- Orcid, X. (2025). - Minimal residual disease as an early endpoint for accelerated drug. Blood Cancer Discovery, 6(1), 13\u201322.","journal-title":"Blood Cancer Discovery"},{"key":"10322_CR5","unstructured":"K, S., et al. (2016). International Myeloma Working Group consensus criteria for response and.\u00a0Lancet Oncol,\u00a017(8), e328\u2013e346."},{"issue":"7","key":"10322_CR6","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry, D. A., et al. (2017). Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis. JAMA Oncology, 3(7), e170580.","journal-title":"JAMA Oncology"},{"issue":"12","key":"10322_CR7","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin, C., Cannova, J., Stock, W., & Muffly, L. (2022). Measurable residual disease in acute lymphoblastic leukemia: Methods and clinical context in adult patients. Haematologica, 107(12), 2783\u20132793.","journal-title":"Haematologica"},{"issue":"1","key":"10322_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi, N. C., et al. (2017). Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis. JAMA Oncology, 3(1), 28\u201335.","journal-title":"JAMA Oncology"},{"issue":"7","key":"10322_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3324\/haematol.2023.284662","volume":"109","author":"R Szalat","year":"2024","unstructured":"Szalat, R., Anderson, K., & Munshi, N. (2024). Role of minimal residual disease assessment in multiple myeloma. Haematologica, 109(7), 2049\u20132059.\u00a0","journal-title":"Haematologica"},{"issue":"5","key":"10322_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony, S., Stahl, M., & Stone, R. M. (2025). Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 100(5), 860\u2013891.","journal-title":"American Journal of Hematology"},{"key":"10322_CR11","doi-asserted-by":"crossref","unstructured":"L, S., et al. (2024). Fifth Edition of the World Health Classification of Tumors of the. Mod Pathol,\u00a037(2), 100397.","DOI":"10.1016\/j.modpat.2023.100397"},{"key":"10322_CR12","doi-asserted-by":"crossref","unstructured":"A, D. A., et al. (2022). International consensus classification of myeloid neoplasms and acute. Blood,\u00a0140(11), 1200\u20131228.","DOI":"10.1182\/blood.2022015850"},{"key":"10322_CR13","doi-asserted-by":"crossref","unstructured":"D, H., et al. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an. Blood,\u00a0140(12), 1345\u20131377.","DOI":"10.1182\/blood.2022016867"},{"key":"10322_CR14","unstructured":"P, D. A., et al. (2023). Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines. J Natl Compr Canc Netw,\u00a021(5), 503\u2013513."},{"issue":"20","key":"10322_CR15","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/jco.2010.32.8500","volume":"29","author":"C R\u00f6llig","year":"2011","unstructured":"R\u00f6llig, C., et al. (2011). Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system. Journal of Clinical Oncology, 29(20), 2758\u201365.","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10322_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajh.25484","volume":"94","author":"BC Medeiros","year":"2019","unstructured":"Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., & Pollyea, D. A. (2019). Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American Journal of Hematology, 94(7), 803\u2013811.\u00a0","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10322_CR17","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.3324\/haematol.2024.285057","volume":"109","author":"A Bataller","year":"2024","unstructured":"Bataller, A., et al. (2024). \u201cOutcomes and genetic dynamics of acute myeloid leukemia at first relapse,\u201d (in eng). Haematologica, 109(11), 3543\u20133556.\u00a0","journal-title":"Haematologica"},{"key":"10322_CR18","doi-asserted-by":"crossref","unstructured":"R, T. M., et al. (2023). Single-cell genotypic and phenotypic analysis of measurable residual. Sci Adv. 9(38).","DOI":"10.1126\/sciadv.adg0488"},{"issue":"8","key":"10322_CR19","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00277-022-04862-3","volume":"101","author":"K Se","year":"2022","unstructured":"Se, K., et al. (2022). Relapse surveillance of acute myeloid leukemia patients in first. Annals of Hematology, 101(8), 1703\u20131710.","journal-title":"Annals of Hematology"},{"key":"10322_CR20","unstructured":"B, A., et al. (2024). Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.\u00a0Haematologica,\u00a0109(11), 3543\u20133556."},{"key":"10322_CR21","doi-asserted-by":"crossref","unstructured":"B, J. T., Y, W. M., & S, R., (2025). Breaking the bone marrow barrier: Peripheral blood as a gateway to.\u00a0Am J Hematol,\u00a0100(4), 638\u2013651. https:\/\/orcid.org.","DOI":"10.1002\/ajh.27586"},{"key":"10322_CR22","doi-asserted-by":"crossref","unstructured":"T, M. M., K, A., N.-S, M., & S, T. (2025). Clonal composition of karyotypically normal AML at diagnosis is not.\u00a0Blood Neoplasia,\u00a02(2).","DOI":"10.1016\/j.bneo.2025.100073"},{"key":"10322_CR23","doi-asserted-by":"crossref","unstructured":"C, G., P, Y., V, T. N. (2024).\u00a0Similarities and differences of bone marrow and peripheral blood samples.\u00a0EJHaem,\u00a05(4), 721\u2013727.\u00a0https:\/\/orcid.org.","DOI":"10.1002\/jha2.961"},{"issue":"3","key":"10322_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","volume":"25","author":"K Jm","year":"2014","unstructured":"K, J. M., et al. (2014). Functional heterogeneity of genetically defined subclones in acute. Cancer Cell, 25(3), 379\u2013392.","journal-title":"Cancer Cell"},{"key":"10322_CR25","doi-asserted-by":"crossref","unstructured":"W, Y., et al. (2023). Multimodal single-cell and whole-genome sequencing of small, frozen.\u00a0Nat Genet,\u00a055(1), 19\u201325.","DOI":"10.1038\/s41588-022-01268-9"},{"key":"10322_CR26","doi-asserted-by":"crossref","unstructured":"M, N., et al. (2024). Pre-emptive detection and evolution of relapse in acute myeloid leukemia.\u00a0Leukemia,\u00a038(8), 1667\u20131673.","DOI":"10.1038\/s41375-024-02300-z"},{"issue":"3","key":"10322_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-82-3-365","volume":"82","author":"B Rd","year":"1975","unstructured":"Rd, B., Cd, B., Rw, M., & La, P. (1975). Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic. Annals of Internal Medicine, 82(3), 365\u20136.","journal-title":"Annals of Internal Medicine"},{"key":"10322_CR28","doi-asserted-by":"crossref","unstructured":"W, J., et al. (2002). Diagnostic utility of bilateral bone marrow examination: Significance of. Cancer,\u00a094(5), 1522\u201331.","DOI":"10.1002\/cncr.10364"},{"key":"10322_CR29","unstructured":"K, R. S., et al. (2024). Data-driven, harmonised classification system for myelodysplastic. Lancet Haematol, 11(11), e862\u2013e872."},{"key":"10322_CR30","unstructured":"K, J. D., et al. (2022). The 5th edition of the World Health Organization Classification of.\u00a0Leukemia,\u00a036(7), 1703\u20131719."},{"issue":"1","key":"10322_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"S Dp","year":"2015","unstructured":"Dp, S., et al. (2015). Clonal hematopoiesis of indeterminate potential and its distinction from. Blood, 126(1), 9\u201316.","journal-title":"Blood"},{"key":"10322_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1303785","volume":"13","author":"AM Cacic","year":"2023","unstructured":"Cacic, A. M., Schulz, F. I., Germing, U., Dietrich, S., & Gattermann, N. (2023). Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential. Frontiers in Oncology, 13, Article 1303785.\u00a0","journal-title":"Frontiers in Oncology"},{"key":"10322_CR33","doi-asserted-by":"crossref","unstructured":"Weeks, L. D., et al. (2023). Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid, 2(5).","DOI":"10.1056\/EVIDoa2200310"},{"issue":"25","key":"10322_CR34","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati, L., et al. (2017). Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 129(25), 3371\u20133378.\u00a0","journal-title":"Blood"},{"key":"10322_CR35","doi-asserted-by":"crossref","unstructured":"P, K. T., et al. (2019). Clinical implications of subclonal TP53 mutations in acute myeloid. Haematologica, 104(3), 516\u2013523.","DOI":"10.3324\/haematol.2018.205013"},{"key":"10322_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Y.","year":"2016","unstructured":"Y., A. L., C., G. A., B., B. M., D., T. E., & O., I. (2016). Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous. Nature Communications, 7, Article 12484.","journal-title":"Nature Communications"},{"issue":"4","key":"10322_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MOH.0000000000000509","volume":"26","author":"S C.","year":"2019","unstructured":"C., S., & L., Y. (2019). P53 involvement in clonal hematopoiesis of indeterminate potential. Current Opinion in Hematology, 26(4), 235\u2013240.","journal-title":"Current Opinion in Hematology"},{"key":"10322_CR38","doi-asserted-by":"crossref","unstructured":"H, M., et al. (2021). Update on MRD in acute myeloid leukemia: A consensus document from.\u00a0Blood,\u00a0138(26), 2753\u20132767.","DOI":"10.1182\/blood.2021013626"},{"issue":"2","key":"10322_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3324\/haematol.2013.090217","volume":"99","author":"RR W.","year":"2014","unstructured":"W., R. R., H., A. P., H., S. M., C.-R., J., & H., D. D. (2014). Acquired ASXL1 mutations are common in patients with inherited GATA2. Haematologica, 99(2), 276\u201381.","journal-title":"Haematologica"},{"key":"10322_CR40","doi-asserted-by":"crossref","unstructured":"W, T. N., et al. (2016). Rapid expansion of preexisting nonleukemic hematopoietic clones. Blood, 127(7), 893\u2013897.","DOI":"10.1182\/blood-2015-10-677021"},{"key":"10322_CR41","doi-asserted-by":"crossref","unstructured":"C, L. V., et al. (2022). Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with. Leukemia, 36(2), 394\u2013402.","DOI":"10.1038\/s41375-021-01368-1"},{"issue":"7","key":"10322_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/0008-5472.CAN-22-0405","volume":"82","author":"JP I.","year":"2022","unstructured":"I., J. P., & O., I. (2022). The two-hit hypothesis meets epigenetics. Cancer Research, 82(7), 1167\u20131169.","journal-title":"Cancer Research"},{"key":"10322_CR43","doi-asserted-by":"crossref","unstructured":"S, J., & H, B. J. P. (2025). Epigenetic dysregulation in acute myeloid leukemia. Seminars in Hematology, 62(3), 177\u2013186.","DOI":"10.1053\/j.seminhematol.2025.06.003"},{"key":"10322_CR44","doi-asserted-by":"crossref","unstructured":"S, C. G., et al. (2009). Long-term follow-up of a population based cohort with monoclonal. British Journal of Haematology, 144(2), 176\u2013184.","DOI":"10.1111\/j.1365-2141.2008.07423.x"},{"key":"10322_CR45","doi-asserted-by":"crossref","unstructured":"Q, K. M., V, D. M., & LG, N. L., (2023). The paradox of aging: Aging-related shifts in T cell function and. Seminars in Immunology, 70(101834).","DOI":"10.1016\/j.smim.2023.101834"},{"issue":"22","key":"10322_CR46","first-page":"08","volume":"32","author":"C J","year":"2021","unstructured":"J, C. (2021). The two-hit theory hits 50. Molecular Biology of the Cell, 32(22), 08\u20130407.","journal-title":"Molecular Biology of the Cell"},{"key":"10322_CR47","doi-asserted-by":"crossref","unstructured":"J, B., et al. (2023). Acute myeloid leukemia causes T cell exhaustion and depletion in a.\u00a0J Immunol,\u00a0211(9), 1426\u20131437.","DOI":"10.4049\/jimmunol.2300111"},{"key":"10322_CR48","doi-asserted-by":"crossref","unstructured":"K, H. A., et al. (2018). Signatures of CD8+ T cell dysfunction in AML patients and their. JCI Insight,\u00a03(21).","DOI":"10.1172\/jci.insight.120974"},{"issue":"4","key":"10322_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12185-016-2153-5","volume":"105","author":"I Mm","year":"2017","unstructured":"Mm, I., & Nab, A. (2017). Bone marrow T-cell percentage: A novel prognostic indicator in acute. International Journal of Hematology, 105(4), 453\u2013464.","journal-title":"International Journal of Hematology"},{"issue":"25","key":"10322_CR50","doi-asserted-by":"publisher","first-page":"14331","DOI":"10.1073\/pnas.1916206117","volume":"117","author":"L Aj","year":"2020","unstructured":"L, A. J., et al. (2020). Reversible suppression of T cell function in the bone marrow. Proc Natl Acad Sci USA, 117(25), 14331\u201314341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"10322_CR51","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","volume":"33","author":"B Kv","year":"2015","unstructured":"Kv, B. (2015). Biomarker: Predictive or prognostic? Journal of Clinical Oncology, 33(33), 3968\u20133971.","journal-title":"Journal of Clinical Oncology"},{"key":"10322_CR52","doi-asserted-by":"crossref","unstructured":"B, F., et al. (2012). Prognostic and therapeutic implications of minimal residual disease. Blood,\u00a0119(2), 332\u201341.","DOI":"10.1182\/blood-2011-08-363291"},{"key":"10322_CR53","doi-asserted-by":"crossref","unstructured":"R.-A, E., et al. (2024). Optimal prognostic threshold for measurable residual disease positivity. Leukemia,\u00a038(10), 2266\u20132269.","DOI":"10.1038\/s41375-024-02378-5"},{"issue":"23","key":"10322_CR54","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","volume":"8","author":"R Fg","year":"2024","unstructured":"R, F. G., et al. (2024). Measurable residual disease monitoring in AML with FLT3-ITD treated with. Blood Advances, 8(23), 6067\u20136080.","journal-title":"Blood Advances"},{"key":"10322_CR55","unstructured":"C, A., Y, W., D. I, M., E, W. E., Y, J. J., & R, G. L. (2023). Bayesian modelling of response to therapy and drug-sensitivity in acute. Res Sq,\u00a01(24)."},{"issue":"25","key":"10322_CR56","first-page":"015","volume":"17","author":"K J.","year":"2016","unstructured":"J., K., W., J., & F., M. (2016). BayesFlow: Latent modeling of flow cytometry cell populations. BMC Bioinformatics, 17(25), 015\u20130862.","journal-title":"BMC Bioinformatics"},{"issue":"8","key":"10322_CR57","first-page":"693","volume":"73","author":"C C.","year":"2008","unstructured":"C., C., F., F., O., J., F., D., W., M., & K., T. B. (2008). Statistical mixture modeling for cell subtype identification in flow. Cytometry. Part A\u202f: the journal of the International Society for Analytical Cytology, 73(8), 693\u2013701.","journal-title":"Cytometry. Part A : the journal of the International Society for Analytical Cytology"},{"key":"10322_CR58","doi-asserted-by":"crossref","unstructured":"J, D., et al. (2024). FDA IDE validation of multiple myeloma MRD test by flow cytometry.\u00a0Am J Hematol,\u00a099(12), 2399\u20132401.","DOI":"10.1002\/ajh.27484"},{"issue":"4-5","key":"10322_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/17474086.2024.2347303","volume":"17","author":"H R.","year":"2024","unstructured":"R., H., & D., R. (2024). Revisiting the role of measurable residual disease in FLT3 mutated acute. Expert Review of Hematology, 17(4\u20135), 103\u2013106.","journal-title":"Expert Review of Hematology"},{"key":"10322_CR60","doi-asserted-by":"crossref","unstructured":"E. E, F., P, A. J., L, S., & Z, A. M. (2025). Pre-emptive therapeutic decisions based on measurable residual disease. Leukemia,\u00a039(1), 1\u20137.","DOI":"10.1038\/s41375-024-02458-6"},{"key":"10322_CR61","doi-asserted-by":"crossref","unstructured":"S, S., et al. (2024). Recommendations from the AML molecular MRD expert advisory board. Leukemia,\u00a038(7), 1638\u20131641.","DOI":"10.1038\/s41375-024-02275-x"},{"key":"10322_CR62","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. (2020). Hematologic malignancies: Regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment guidance for industry. FDA Guidance Document. FDA-2018-D-3090."},{"key":"10322_CR63","doi-asserted-by":"crossref","unstructured":"L, Y., et al. (2023). NGS-defined measurable residual disease (MRD) after initial chemotherapy.\u00a0Blood Cancer J,\u00a013(1), 023\u201300833.","DOI":"10.1038\/s41408-023-00833-7"},{"key":"10322_CR64","doi-asserted-by":"crossref","unstructured":"T, F., et al. (2018). Measurable residual disease monitoring by NGS before allogeneic.\u00a0Blood,\u00a0132(16), 1703\u20131713.","DOI":"10.1182\/blood-2018-02-829911"},{"issue":"1","key":"10322_CR65","first-page":"000000000000067","volume":"6","author":"T Jm","year":"2021","unstructured":"T, J. M., et al. (2021). Technical aspects of flow cytometry-based measurable residual disease. Hemasphere, 6(1), 0000000000000676.","journal-title":"Hemasphere"},{"issue":"2","key":"10322_CR66","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrg3642","volume":"15","author":"D Sims","year":"2014","unstructured":"Sims, D., Sudbery, I., Ilott, N. E., Heger, A., & Ponting, C. P. (2014). Sequencing depth and coverage: Key considerations in genomic analyses. Nature Reviews. Genetics, 15(2), 121\u201332.","journal-title":"Nature Reviews. Genetics"},{"issue":"5","key":"10322_CR67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/gepi.22048","volume":"41","author":"P Liao","year":"2017","unstructured":"Liao, P., Satten, G. A., & Hu, Y. J. (2017). PhredEM: A phred-score-informed genotype-calling approach for next-generation sequencing studies. Genetic Epidemiology, 41(5), 375\u2013387.","journal-title":"Genetic Epidemiology"},{"issue":"3","key":"10322_CR68","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/ijlh.12068","volume":"35","author":"BD Hedley","year":"2013","unstructured":"Hedley, B. D., & Keeney, M. (2013). Technical issues: Flow cytometry and rare event analysis. International Journal of Laboratory Hematology, 35(3), 344\u201350.\u00a0","journal-title":"International Journal of Laboratory Hematology"},{"key":"10322_CR69","doi-asserted-by":"crossref","unstructured":"Cloos, J., et al. (2025). 2025 update on MRD in acute myeloid leukemia: A consensus document from the ELN-DAVID MRD Working Party. Blood.","DOI":"10.1182\/blood.2025031480"},{"key":"10322_CR70","unstructured":"N, M., et al. (2017). Minimal residual disease by either flow cytometry or cytogenetics prior. Blood Cancer J,\u00a07(12), 017\u20130007."},{"issue":"9","key":"10322_CR71","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/cncr.26539","volume":"118","author":"F M","year":"2012","unstructured":"M, F., B, S., B, W., B, G., Bm, S., & Fr, A. (2012). Prognostic impact of discordant results from cytogenetics and flow. Cancer, 118(9), 2411\u20139.","journal-title":"Cancer"},{"key":"10322_CR72","doi-asserted-by":"crossref","unstructured":"D, E. J., et al. (2022). Genomic profiling for clinical decision making in myeloid neoplasms and.\u00a0Blood,\u00a0140(21), 2228\u20132247.","DOI":"10.1182\/blood.2022015853"},{"issue":"3","key":"10322_CR73","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/applmicrobiol1030028","volume":"1","author":"S Park","year":"2021","unstructured":"Park, S., Rana, A., Sung, W., & Munir, M. (2021). Competitiveness of quantitative polymerase chain reaction (qPCR) and droplet digital polymerase chain reaction (ddPCR) technologies, with a particular focus on detection of antibiotic resistance genes (ARGs). Applied Microbiology, 1(3), 426\u2013444.","journal-title":"Applied Microbiology"},{"key":"10322_CR74","unstructured":"L, E. W., et al. (2024). FLT3-TKD measurable residual disease detection using droplet digital PCR.\u00a0Int J Mol Sci,\u00a025(11)."},{"issue":"Supplement 1","key":"10322_CR75","first-page":"6167","volume":"144","author":"GR L\u00f3pez","year":"2024","unstructured":"L\u00f3pez, G. R., et al. (2024). Comparative analysis of NGS and digital PCR for measurable residual disease monitoring in intensively treated acute myeloid leukemia patients. ASH Annual Meeting, Bood, Ed., 144(1), 6167.","journal-title":"ASH Annual Meeting, Bood, Ed."},{"key":"10322_CR76","doi-asserted-by":"crossref","unstructured":"L, G. A., V, M. R., & E, E. E. (2020). Long-read human genome sequencing and its applications. Nat Rev Genet,\u00a021(10), 597\u2013614.","DOI":"10.1038\/s41576-020-0236-x"},{"key":"10322_CR77","doi-asserted-by":"crossref","unstructured":"S, H., et al. (2023). Next-generation sequencing technology: Current trends and advancements.\u00a0Biology,\u00a012(7).","DOI":"10.3390\/biology12070997"},{"key":"10322_CR78","doi-asserted-by":"crossref","unstructured":"D, S., et al. (2020). Sensitive and broadly applicable residual disease detection in acute. Am J Hematol,\u00a095(10), 1148\u20131157.","DOI":"10.1002\/ajh.25918"},{"key":"10322_CR79","doi-asserted-by":"crossref","unstructured":"B, F., et al. (2022). Clinical relevance of an objective flow cytometry approach based on limit.\u00a0Haematologica,\u00a0107(12), 2823\u20132833.","DOI":"10.3324\/haematol.2021.279777"},{"key":"10322_CR80","unstructured":"G, R., et al. (2021). Assessment of protocol impact on subjectivity uncertainty when analyzing. Methods Protoc,\u00a04(2)."},{"key":"10322_CR81","doi-asserted-by":"crossref","unstructured":"G, R., et al. (2021). Quantifying operator subjectivity within flow cytometry data analysis as. PDA J Pharm Sci Technol,\u00a075(1), 33\u201347.","DOI":"10.5731\/pdajpst.2019.011213"},{"issue":"7","key":"10322_CR82","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nri.2016.56","volume":"16","author":"S Y","year":"2016","unstructured":"Y, S., G. S, V., & Bn, L. (2016). Computational flow cytometry: Helping to make sense of high-dimensional. Nature Reviews Immunology, 16(7), 449\u201362.","journal-title":"Nature Reviews Immunology"},{"key":"10322_CR83","doi-asserted-by":"crossref","unstructured":"F, R., et al. (2022). Transformation of multicolour flow cytometry data with OTflow prevents.\u00a0Cytometry A,\u00a0101(1), 72\u201385.","DOI":"10.1002\/cyto.a.24491"},{"issue":"9","key":"10322_CR84","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","volume":"36","author":"R Ma","year":"2022","unstructured":"R, M. A., et al. (2022). Reproducible measurable residual disease detection by multiparametric. Leukemia, 36(9), 2208\u20132217.","journal-title":"Leukemia"},{"issue":"11","key":"10322_CR85","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1182\/blood.V97.11.3574","volume":"97","author":"B Mr","year":"2001","unstructured":"B, M. R., et al. (2001). High frequency of immunophenotype changes in acute myeloid leukemia at. Blood, 97(11), 3574\u20133580.","journal-title":"Blood"},{"key":"10322_CR86","unstructured":"G.-A, M., et al. (2023). Single-cell DNA sequencing and immunophenotypic profiling to track clonal.\u00a0Biomedicines,\u00a012(1)."},{"key":"10322_CR87","doi-asserted-by":"crossref","unstructured":"T, F., et al. (2022). Genetic diversity within leukemia-associated immunophenotype-defined.\u00a0Ann Hematol,\u00a0101(3), 571\u2013579.","DOI":"10.1007\/s00277-021-04747-x"},{"key":"10322_CR88","doi-asserted-by":"crossref","unstructured":"R, J., et al. (2021). Multiplex assays for the identification of serological signatures of. Lancet Microbe,\u00a02(2), e60\u2013e69.","DOI":"10.1016\/S2666-5247(20)30197-X"},{"key":"10322_CR89","doi-asserted-by":"crossref","unstructured":"R, G., et al. (2020). Leukemia-associated immunophenotypes subdivided in \u201ccategories of\".\u00a0Cytometry B Clin Cytom,\u00a098(3), 216\u2013225.","DOI":"10.1002\/cyto.b.21855"},{"key":"10322_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2021.114210","volume":"627","author":"S Holmberg-Thyden","year":"2021","unstructured":"Holmberg-Thyden, S., Gr\u00f8nb\u00e6k, K., Gang, A. O., El Fassi, D., & Hadrup, S. R. (2021). A user\u2019s guide to multicolor flow cytometry panels for comprehensive immune profiling. Analytical Biochemistry, 627, Article 114210.","journal-title":"Analytical Biochemistry"},{"issue":"1","key":"10322_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86792-4","volume":"15","author":"A Zein-Sabatto","year":"2025","unstructured":"Zein-Sabatto, A., St Angelo, K., Madnick, S. J., Hoffman-Kim, D., Morgan, J. R., & Lee, J. (2025). Multi-assay assessment of cytotoxicity reveals multiple mechanisms of action in 3D microtissues. Scientific Reports, 15(1), Article 3090.","journal-title":"Scientific Reports"},{"key":"10322_CR92","doi-asserted-by":"crossref","unstructured":"A, R., et al. (2017). FISH-Flow, a protocol for the concurrent detection of mRNA and protein in. Nat Protoc,\u00a012(6), 1245\u20131260.","DOI":"10.1038\/nprot.2017.039"},{"key":"10322_CR93","doi-asserted-by":"crossref","unstructured":"T, T., et al. (2023). Imaging flow cytometry-based multiplex FISH for three IGH translocations. J Hum Genet,\u00a068(7), 507\u2013514.","DOI":"10.1038\/s10038-023-01136-2"},{"key":"10322_CR94","doi-asserted-by":"crossref","unstructured":"Z, L., & S, J. W. (2017). Multiple roles of APC and its therapeutic implications in colorectal. J Natl Cancer Inst,\u00a0109(8).","DOI":"10.1093\/jnci\/djw332"},{"key":"10322_CR95","doi-asserted-by":"crossref","unstructured":"K, D., et al. (2023). Molecular residual disease and efficacy of adjuvant chemotherapy in. Nat Med,\u00a029(1), 127\u2013134.","DOI":"10.1038\/s41591-022-02115-4"},{"key":"10322_CR96","doi-asserted-by":"crossref","unstructured":"T, J., et al. (2022). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon. N Engl J Med,\u00a0386(24), 2261\u20132272.","DOI":"10.1056\/NEJMoa2200075"},{"issue":"1","key":"10322_CR97","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/j.clml.2020.08.003","volume":"21","author":"B R","year":"2021","unstructured":"R, B., T, K., Ka, G., M, S., V, R., & S, K. (2021). Impact of CD138 magnetic bead-based positive selection on bone marrow. Clinical Lymphoma, Myeloma & Leukemia, 21(1), e48\u2013e51.","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10322_CR98","unstructured":"M, K., et al. (2020). Clonal evolution of acute myeloid leukemia revealed by high-throughput. Nat Commun,\u00a011(1), 020\u201319119."},{"issue":"4","key":"10322_CR99","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/2643-3230.BCD-21-0046","volume":"2","author":"D Lw","year":"2021","unstructured":"D, L. W., et al. (2021). Personalized single-cell proteogenomics to distinguish acute myeloid. Blood Cancer Discov, 2(4), 319\u2013325.","journal-title":"Blood Cancer Discov"},{"key":"10322_CR100","doi-asserted-by":"crossref","unstructured":"Pierola, A. A., et al. (2023). Minimal residual disease detection by single cell DNA sequencing technology: A feasible approach for clinical application and identification of the landscape of MRD clones.\u00a0ASH Annual Conference, 142(1), 2958.","DOI":"10.1182\/blood-2023-188865"},{"issue":"2","key":"10322_CR101","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P., & Trumpp, A. (2023). Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica, 108(2), 353\u2013366.","journal-title":"Haematologica"},{"issue":"2","key":"10322_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0170-3","volume":"9","author":"M Yilmaz","year":"2019","unstructured":"Yilmaz, M., et al. (2019). Late relapse in acute myeloid leukemia (AML): Clonal evolution or therapy-related leukemia? Blood Cancer Journal, 9(2), Article 7.","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"10322_CR103","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000554","volume":"5","author":"M Tesio","year":"2021","unstructured":"Tesio, M. (2021). Stemness and relapse: \u201cChicken or the egg\" question. Hemasphere, 5(4), Article e554.","journal-title":"Hemasphere"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10322-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:28:18Z","timestamp":1774603698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":103,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10322"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10322-5","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}